Trialspark Revenue and Competitors

Location

$156M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Trialspark's estimated annual revenue is currently $29.4M per year.(i)
  • Trialspark's estimated revenue per employee is $155,000
  • Trialspark's total funding is $156M.
  • Trialspark's current valuation is $1B.

Employee Data

  • Trialspark has 190 Employees.(i)
  • Trialspark grew their employee count by 15% last year.

Trialspark's People

NameTitleEmail/Phone
1
Head Investments & VP Business DevelopmentReveal Email/Phone
2
CEO and Co-founder at TrialSparkReveal Email/Phone
3
VP Regulatory AffairsReveal Email/Phone
4
Head Medical Writing (Sr. Director)Reveal Email/Phone
5
VP ProductReveal Email/Phone
6
VP, Program ManagementReveal Email/Phone
7
Head LegalReveal Email/Phone
8
VP, BiostatisticsReveal Email/Phone
9
VP Quality AssuranceReveal Email/Phone
10
SVP, Therapeutic Head RheumatologyReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$0.6M4-20%N/AN/A
#2
$6.7M438%N/AN/A
#3
$34.4M222-1%N/AN/A
#4
$5.2M670%$10MN/A
#5
$2M130%N/AN/A
#6
$7.5M370%$51.6MN/A
#7
$0.3M2-50%N/AN/A
#8
$4.3M21-16%$3.3MN/A
#9
$3.6M230%N/AN/A
#10
$4.3M56-8%$118MN/A
Add Company

What Is Trialspark?

Trialspark is a software and technology company that accelerates the discovery of new drugs and medical treatments by reimagining the clinical trial process. Today, clinical trials are incredibly inefficient. A single clinical trial can cost more than 100 million dollars and less than 10% of clinical trials are completed on time. Our mission is to bring life saving treatments to patients faster by addressing these inefficiencies.

keywords:Biotechnology, Healthcare, Pharmaceuticals, Health Care Information Technology, Technology, Clinical Trials, Science

$156M

Total Funding

190

Number of Employees

$29.4M

Revenue (est)

15%

Employee Growth %

$1B

Valuation

N/A

Accelerator

Trialspark News

2021-10-02 - US-based Clinical trials vendor TrialSpark raises USD 156 million in Series C round

TrialSpark, a New York-based biotech unicorn, raised USD 156 million in a Series C round led by tech investors Sam Altman and Lachy Groom on 1 October 2021. Investors: Tech investors Sam Altman and Lachy Groom led the latest round of funding with participation from new and existing investors, i ...

2021-09-30 - TrialSpark Raises $156M in Series C Funding

TrialSpark, a NYC-based next generation pharma company, raised $156MM in Series C funding. The round was led by Sam Altman and Lachy Groom, with participation from new and existing investors, including Sequoia Capital (Series A lead), Thrive Capital (Series B lead), Casdin Capital, Dragoneer, S ...

2021-05-26 - TrialSpark and Sanofi announce collaboration to accelerate COPD clinical development

NEW YORK, May 26, 2021 /PRNewswire/ -- TrialSpark Inc., a tech-enabled drug development company dedicated to improving the speed, quality, and innovation of clinical trials, announced a collaboration today with global biopharmaceutical company Sanofi. Together, the companies will execute clini ...

2019-01-02 - Novartis, TrialSpark Collaborate to Maximize Patient Access to Clinical

TrialSpark, a technology company that works to increase access and integrate trial participation into patients' everyday lives, has teamed up

2018-12-12 - TrialSpark debuts first clinical trial sites as part of deal with Novartis

New York-based tech CRO TrialSpark launched its first clinical trial sites as part of a partnership with Novartis that takes a new direction.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$28.6M19012%$123M
#2
$34.3M190-36%$342.1M
#3
$52.3M1901%N/A
#4
$7.5M1906%N/A
#5
$56.4M1902%N/A